Mediagnost is one of the partners in the project „PAS GRAS” to promote with innovative in-vitro-diagnostic tests the health of children, adolescents and young adults, funded by the EU with 9.5 million €
Pressemitteilung | mediagnost GmbH
„PAS GRAS: De-risking metabolic, environmental and behavioral determinants of obesity in children, adolescents and young adults“
University of Coimbra leads project funded by the European Commission with 9.5 million euros to fight obesity and promote health throughout life.
The project “PAS GRAS: de-risking metabolic, environmental and behavioral determinants of obesity in children, adolescents and young adults”, led by the researcher and vice-president of the Center for Neuroscience and Cell Biology of the University of Coimbra (CNC-UC), Paulo Oliveira, has just received 9.5 million euros from Horizon Europe. “PAS GRAS” involves partners from 8 European countries and aims to develop interdisciplinary research and innovation strategies over a five-year period that can change the paradigm of obesity prevention and treatment, providing practical solutions for a healthy life in contemporary society.
The research will clarify the roles of lifestyle, mental health, family history, socioeconomic factors and the environment in the development of obesity, and their interaction with the genetic and metabolic characteristics of each individual. Based on an integrated analysis of multiple parameters, it will be possible to develop a personalized and robust assessment of the increased risk of obesity and associated complications, which include, for example, cardiovascular problems. The study will target children (3-9 years old), adolescents (10-18 years old), young adults (19-25 years old), and their families, who are overweight or obese. Additionally, the project will study cellular and molecular mechanisms underlying the protective effects of Mediterranean diet components and physical activity. Furthermore, it will create an international campaign aimed at increasing health literacy and raising awareness in society about the risks of obesity.
«PAS GRAS will fill critical gaps in the diagnosis and prognosis of obesity and provide a set of innovative tools and measures that can contribute to adopting and maintaining lifestyle choices that counteract overweight/obesity», explains the project leader. Paulo Oliveira further adds that «PAS GRAS is one of the 6 projects funded at the European level. The project has a unique team, involving not only citizens, researchers, health professionals and entrepreneurs, but also local authorities, and national and international authorities, so that together we can reverse the upward obesity curve, especially in the younger populations».
The project will involve the participation of 15 entities, including Mediagnost GmbH.
The task of Mediagnost in PAS GRAS is to develop and establish innovative multiplex immunoassays for the detection of the novel biomarkers identified by the projectpartners.
About the company:
Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH, founded in 1985, is a research based company dedicated to the development and manufacture of in-vitro diagnostic test systems and cell culture derived biological reagents (viral antigens and antibodies). Main focus lies on designing innovative diagnostic tools in Endocrinology, Virology, Infectiology, Immunoassay based and with Nucleic Acid Technology, in a swift transfer from the scientific research base directly to the customer.
Bildrechte: mediagnost GmbH
Dr. Lutz Pridzun
CEO | Production Manager
+49 7121 514 840
Aspenhaustrasse 25, 72770 Reutlingen, Deutschland / Germany
TEL +49 (0) 7121 514 840 FAX +49 (0) 7121 5148410 www.mediagnost.de